Notably, the activation of IRF5 and ISGs in the active and remission phases of SLE suggests that the therapeutic effects of inhibiting IRF5 are better than those of full inhibition of IFN-I signaling in Lyn-deficient lupus mice (74). The gene discussed is IRF5; the disease is systemic lupus erythematosus.